Adaptive Radiation and Chemo for Rectal Cancer
Part of Cancer, Digestive system clinical trials.
This trial tests a personalized approach to treating rectal cancer before surgery. Doctors will adjust radiation therapy during treatment based on how well your tumor is shrinking, combined with chemotherapy drugs to improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Confirmed rectal cancer diagnosis (adenocarcinoma type)
- Cancer is in the lower rectum (within 12 cm of the anal opening)
- Cancer stage T2-T4, with or without lymph node involvement
- No cancer spread to distant organs (liver, lungs, etc.)
- Good overall health (able to walk and care for yourself with minimal help)
- Age 18–80 years
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is studying different treatments for patients with early-stage rectal cancer that has a higher chance of coming back after local removal. It looks at whether adding radiation or chemoradiation after local surgery can improve outcomes.
This trial tests giving targeted radiation, chemotherapy, and immunotherapy before surgery to shrink locally advanced rectal cancer. It aims to improve treatment results for patients whose tumors have not spread but are at high risk of coming back.
This trial tests a shorter course of radiation combined with chemotherapy and immunotherapy before surgery for high-risk rectal cancer. The goal is to see if this combination shrinks the tumor more effectively and improves outcomes.
This trial tests a treatment plan involving radiation, chemotherapy, and an immunotherapy drug (a PD-1 inhibitor) for people with a specific type of high-risk rectal cancer. The goal is to see if this combination helps shrink the tumor before surgery.
This trial tests a combination of short course radiation therapy, chemotherapy, and two immunotherapy drugs for people with a specific type of rectal cancer that is locally advanced but can still be removed by surgery. It may offer a more effective treatment option for those with mismatch repair proficient (pMMR) or microsatellite stable (MSS) tumors.
This trial combines a special type of radiation (MRI-guided adaptive radiotherapy) with an immunotherapy drug (PD-1 antibody) and chemotherapy (CAPOX) for locally advanced rectal cancer. The goal is to see if this combination can improve treatment outcomes.
Hear when a new Locally Advanced Rectal Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.